Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

LIGAND PHARMACEUTICALS INC.

(LGND)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Lemelson Capital Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Calls on US Attorney to Investigate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/30/2019 | 11:31am EDT

SHELBURNE, Vt., July 30, 2019 /PRNewswire/ -- Lemelson Capital Management (LCM), a private investment management firm, today announced that it had increased its short position in Ligand Pharmaceuticals (NASDAQ: LGND).  The firm today also called on the US Attorney's office for the Southern District of California to investigate Ligand for alleged criminal violations of federal securities laws amidst what LCM has called SEC failures.

LCM's 2014-2018 research and commentary charted the alleged fraud.  As of today, Ligand's shares continue to plummet,1 contributing to a drop in the share price of as much as 65 percent since late September 2018, and destroying billions of dollars in shareholder value, even as markets recently achieved record highs.

To read Lemelson's prior research reports and commentary on Ligand click here

"Sadly, investors have been ruined by Ligand's alleged scheme while the SEC has ignored the red flags and botched opportunities for a proper investigation of the company," said Lemelson Capital's Chief Investment Officer Fr. Emmanuel Lemelson

Disclosure:  LCM is currently short shares of LGND for its clients and has been charged by the SEC in connection with its prior commentary on Ligand.  LCM has denied all charges and is actively defending the matter.

About Lemelson Capital Management

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments. For more information, visit: http://www.lemelsoncapital.com or follow on Twitter @LemelsonCapital

About Rev. Fr. Emmanuel Lemelson:

Rev. Fr. Emmanuel Lemelson is the Chief Investment Officer of Lemelson Capital Management, LLC, follow his work at www.amvona.com or on Twitter @Lemelson

For further information, please contact:

Lemelson Capital Management, LLC 
Investor and Media Relations 
Telephone: 802-332-3833

1 Shares fell about 12 percent today following the company's earnings release.

Cision
View original content:http://www.prnewswire.com/news-releases/lemelson-capital-increases-short-position-in-ligand-pharmaceuticals-nasdaq-lgnd-calls-on-us-attorney-to-investigate-300893239.html

SOURCE Lemelson Capital Management, LLC


© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIGAND PHARMACEUTICALS INC
09/06PG&E's Wildfire Mistakes Followed Years of -2-
DJ
09/05A 'CAT AND MOUSE GAME' : PG&E's Long Record of -2-
DJ
08/29LIGAND PHARMACEUTICALS : to Participate in the H. C. Wainwright 21st Annual Glob..
BU
08/13LIGAND PHARMACEUTICALS : Partner CASI Pharmaceuticals Launches EVOMELA in China
AQ
08/12LIGAND PHARMACEUTICALS : Partner CASI Pharmaceuticals Launches EVOMELA® in China
BU
08/08LIGAND PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
07/30LEMELSON CAPITAL INCREASES SHORT POS : LGND), Calls on US Attorney to Investigat..
PR
07/30LIGAND : 2Q Earnings Snapshot
AQ
07/30LIGAND PHARMACEUTICALS INC : Results of Operations and Financial Condition (form..
AQ
07/30LIGAND PHARMACEUTICALS : Reports Second Quarter 2019 Financial Results
BU
More news